BPC September 11 update

​Galapagos GLPG mid-stage trial success +9%; Cassava SAVA conference call Monday

Price and Volume Movers

Galapagos NV (NASDAQ: GLPG) announced that top-line data from its Phase 2a NOVESA clinical trial with ziritaxestat (GLPG1690) in patients with diffuse cutaneous systemic sclerosis (dcSSc) met the primary endpoint showing a statistically significant change from baseline in the modified Rodnan Skin Score (mRSS) at Week 24, of -8.3 vs -5.7 for placebo. Shares closed up 9% to $136.85.

Cassava Sciences, Inc. (NASDAQ:SAVA) announced that it will hold a conference call on Monday, September 14 at 8:30 a.m. EST. No information was supplied as to the nature of the call. However, the company has guided that final data from its Phase 2b trial in patients with Alzheimer’s disease would be released in September so one would assume that the call is related to this. The company announced in May earlier this year that the trial did not meet its primary endpoint.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Cleveland BioLabs, Inc. (CBLI): $2.33; +23%.

Biofrontera AG (BFRA): $8.78; +19%.

Checkpoint Therapeutics, Inc. (CKPT): $3.32; +19%.

Vascular Biogenics Ltd. (VBLT): $1.35; +18%.

Zymeworks Inc. (ZYME): $38.27; +18%.

DECLINERS:

Evofem Biosciences, Inc. (EVFM): $2.10; -23%.

Corbus Pharmaceuticals Holdings, Inc. (CRBP): $1.88; -17%.

Adamas Pharmaceuticals, Inc. (ADMS): $4.30; -15%.

Satsuma Pharmaceuticals, Inc. (STSA): $4.83; -14%.

Savara Inc. (SVRA): $1.19; -12%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ABBV – AbbVie Inc.
ABBV-951
Parkinson's disease

Phase 3 Phase 3 data due late-2021.
$159 billion

ATRA – Atara Biotherapeutics Inc.
ATA188
Multiple sclerosis

Phase 1a Phase 1b commencement of enrollment announced June 17, 2020. Phase 1a 12-month data September 11, 2020 noted treatment was well-tolerated with no dose-limiting toxicities and no fatal adverse events.
$1.2 billion

CLSD – Clearside Biomedical Inc.
AU-011
Primary choroidal melanoma

Phase 2 Phase 2 initiation of dosing announced September 11, 2020.
$80.2 million

GLPG – Galapagos NV
GLPG1690 - NOVESA
Systemic sclerosis

Phase 2 Phase 2 trial met primary endpoint - September 10, 2020.
$9.1 billion

SAVA – Cassava Sciences Inc.
PTI-125
Alzheimer’s disease

Phase 2b Phase 2b trial did not meet primary endpoint - May 15, 2020. Noted improvements in biomarkers of disease pathology September 14, 2020.
$250.9 million